We are developing a GD2 CAR NKT product (CMD-501) for the treatment of neuroblastoma and small cell lung cancer. CMD-501 is an autologous cell therapy which utilizes our natural killer T (NKT) cell platform technology in combination with genetically engineered chimeric antigen receptors (CARs) and secretion of the IL-15 cytokine to sustain the activity of the therapeutic cells within the immunosuppressive tumor microenvironment. A first-in-human study is underway at Baylor College of Medicine (BCM) at Texas Children’s Hospital in Houston, TX